NXS 0.00% 20.0¢ next science limited

re-read the december quarterly

  1. 1,137 Posts.
    Given some of the concerns aired on this thread regarding the future of Nxs in light of Longtom issues, I had a re-read of the December quarterly issued only 7 weeks ago.

    In summary

    Longtom producing well- revenues of 28.6 million ytd.
    Longtom 5 travelling well
    Echuca scholes progressing
    Crux partnership going well
    Cashflow good
    Admin costs good

    And so on.

    I dont think this Longtom issue is going to have much impact. It was out for 3 months last year so we have been through this before. Cash balance up 3m for quarter and interests costs based on current financing under control.

    Doesnt read like a company on a knife edge. No divestment at the moment, longtom down but otherwise travelling fine and meeting strategic objectives.
 
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.